Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children?

Raphaël, Martine F.; Boer, Anne M. den; Kollen, Wouter J.W.; Mekelenkamp, Hilda; Abbink, Floor; Kaspers, Gertjan J. L.; Zomer-Kooijker, Kim; Molmans, Barbara H. W.; Tissing, Wim J. E.

doi:10.1007/s00520-013-2015-0

Cited by 24 publications

(27 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, other research did not confirm the effectiveness of caphosol. In a double-blinded placebo-controlled randomized trial conducted by Raphael et al on a group of 29 patients, where 15 of them received caphosol, the therapeutic use of caphosol was not beneficial in the treatment of oral mucositis in comparison to the placebo [66]. A similar conclusion was presented by Rao et al in a phase II multicenter trial conducted on 98 patients receiving head and neck radiation.…”

Section: Management Of Oral Mucositissupporting

confidence: 52%

Oncological-Therapy Related Oral Mucositis as an Interdisciplinary Problem—Literature Review

Kusiak

Jereczek‐Fossa

Cichońska

et al. 2020

IJERPH

View full text Add to dashboard Cite

Oral mucositis is a toxic side effect of non-surgical cancer treatments: chemotherapy and radiotherapy, which strongly impair quality of life and can not only cause strong pain, but also lead to problems with basic physiological needs as eating and swallowing. Development of oral mucositis is associated with type, dosage, and schedule of radiation or chemotherapy and other factors related to patients. Management of oral mucositis is a valid problem, requiring topical application of anesthetics, coating agents, cryotherapy, low level laser therapy, pharmacological methods as usage of keratinocyte growth factors, supplementation of vitamins, and a proper diet. Another approach to oral mucositis measurement includesphotobiomodulation, which brings analgesic and anti-inflammatory effects.Although oral mucositis is a general health issues, the role of proper dental care is essential. It should include elimination of all potential sources of mucosal injury and microorganisms inhabiting theoral cavity through oral hygiene education, professional management ofdental plaque, and treatment of the caries and periodontium, which are necessary to reduce the risk of inflammation in the oral cavity. This paper describes the possibilities of monitoring oral mucositis, taking into account the latest therapeutic achievements.

show abstract

Section: Management Of Oral Mucositissupporting

confidence: 52%

Oncological-Therapy Related Oral Mucositis as an Interdisciplinary Problem—Literature Review

Kusiak

Jereczek‐Fossa

Cichońska

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…Raphael et al (2014) reported a prospective multicentre double-blind randomised controlled trial evaluating interventional (rather than preventive) Caphosol vs 0.9% saline placebo in children (4–18 years old) undergoing chemotherapy alone or HCT. Study rinses were initiated following onset of OM, and all end points between the two groups were similar.…”

Section: Discussionmentioning

confidence: 99%

“…The study by Svanberg et al (2015) reported one subject who stopped Caphosol rinses because of disagreeable taste. Of note, the study by Raphael et al (2014) was conducted in children aged 4 to 18 years randomised to NaCl 0.9% or Caphosol and reported that no patients dropped out because of intolerance/bad taste, although compliance was not described. In the current study, the reason for missed rinses was only collected when no daily rinses were completed, but not when less than four were completed; therefore, the true extent to which taste/tolerability (or other factors) affected compliance (in either study arm) is unknown.…”

Section: Discussionmentioning

confidence: 99%

“…In all clinical reports, Caphosol has been consistently well tolerated with no reported side effects or toxicities (Quinn, 2013). However, the efficacy of Caphosol has not been replicated in other blinded and randomised studies and, in particular, definitive studies in pediatric patients have been few (Raphael et al , 2014). The primary objective of this Children's Oncology Group (COG) multicentre trial was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe OM compared with placebo saline solution among children and adolescents undergoing myeloablative HCT.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation

et al. 2016

View full text Add to dashboard Cite

Background:The primary objective was to determine whether topically administered Caphosol, rinsed orally four times daily at the initiation of conditioning, reduces the duration of severe oral mucositis (OM) compared with placebo among children and adolescents undergoing haematopoietic cell transplantation (HCT).Methods:This was a Children's Oncology Group multicentre randomised double-blinded placebo-controlled clinical trial. Patients between the ages of 4 and 21 years who were scheduled to undergo myeloablative HCT for any indication were randomised to Caphosol or placebo saline rinses four times daily from initiation of conditioning through day +20. Subjects were assessed daily for OM using the World Health Organisation (WHO) Oral Toxicity Scale, Mouth Pain Categorical Scale (0–10) and the Oral Mucositis Daily Questionnaire (OMDQ). The primary end point was duration of severe OM (WHO ⩾3).Results:The study enrolled 220 participants with a median age of 13.7 years (range 4.0–21.9); 163 (74%) received allogeneic HCT. The mean (±s.d.) duration of severe OM was not reduced among Caphosol (4.5±5.0 days) vs placebo (4.5±4.8; P=0.99) recipients. The incidence of severe OM in the Caphosol and placebo arms was 63% (57 out of 91) and 68% (62 out of 91), respectively (P=0.44). There were no significant differences in any of the secondary end points between the groups.Conclusions:Caphosol did not reduce severe OM when compared with placebo among children and adolescents undergoing myeloablative HCT. Studies to identify effective interventions for OM are needed in this population.

show abstract

“…However, data on the efficacy of these agents in controlling mucositis-related symptoms are scarce [13,21,22,23,24]. …”

Section: Mucositis Managementmentioning

confidence: 99%

Oral Mucositis: Melatonin Gel an Effective New Treatment

Moneim

Guerra‐Librero

Florido

et al. 2017

IJMS

View full text Add to dashboard Cite

The current treatment for cervico-facial cancer involves radio and/or chemotherapy. Unfortunately, cancer therapies can lead to local and systemic complications such as mucositis, which is the most common dose-dependent complication in the oral cavity and gastrointestinal tract. Mucositis can cause a considerably reduced quality of life in cancer patients already suffering from physical and psychological exhaustion. However, the role of melatonin in the treatment of mucositis has recently been investigated, and offers an effective alternative therapy in the prevention and/or management of radio and/or chemotherapy-induced mucositis. This review focuses on the pathobiology and management of mucositis in order to improve the quality of cancer patients’ lives.

show abstract

Caphosol, a therapeutic option in case of cancer therapy-induced oral mucositis in children?

Cited by 24 publications

References 10 publications

Oncological-Therapy Related Oral Mucositis as an Interdisciplinary Problem—Literature Review

Oncological-Therapy Related Oral Mucositis as an Interdisciplinary Problem—Literature Review

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation

Oral Mucositis: Melatonin Gel an Effective New Treatment

Contact Info

Product

Resources

About